Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics (NASDAQ: ANGO) reported fiscal Q2 2026 results: net sales $79.4M (+8.8% pro forma) and Med Tech sales $35.7M (+13.0%). GAAP net loss was $6.4M (loss per share $0.15) and adjusted loss per share was $0.00. Adjusted EBITDA was $5.9M and cash was $41.6M.
The company secured three regulatory milestones for its Mechanical Thrombectomy portfolio (APEX-Return IDE, PAVE IDE, modified AlphaVac 510(k)), concluded patent litigation with Bard, and raised FY2026 net sales guidance to $312–$314M and adjusted EBITDA to $8–$10M. CEO Jim Clemmer will retire upon successor appointment expected in fiscal 2027.
AngioDynamics (NASDAQ: ANGO) will report fiscal 2026 second quarter results before the market open on Tuesday, January 6, 2026. Management will host a conference call at 8:00 AM ET the same day to discuss results. Investors can join by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international) or via webcast in the company Investors section at www.angiodynamics.com.
A webcast replay will be available about one hour after the call and a recorded playback will be accessible until Tuesday, January 13, 2026 at 11:59 PM ET by dialing 1-844-512-2921 (domestic) or +1-412-317-6671 (international) using passcode 13757614.
AngioDynamics (NASDAQ: ANGO) announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026.
The presentation will begin at 3:00 p.m. PT. A live webcast will be accessible via the company’s Investors section at www.angiodynamics.com and will be available for replay after the event.
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, Nov. 10, 2025 at 8:00 a.m. ET. A live webcast will be available via the company’s Investors webpage and a replay will be posted after the event.
The presentation offers investors a chance to hear management discuss strategy, financial priorities, and market outlook for the company.
AngioDynamics (NASDAQ: ANGO) said its NanoKnife System was named to TIME’s 2025 Best Inventions in Medical and Healthcare for its use of Irreversible Electroporation (IRE) to ablate prostate tissue while preserving nearby structures.
The company noted a U.S. FDA 510(k) clearance in late 2024, publication of the PRESERVE study (121 patients, 17 sites) showing 84% free from in-field clinically significant disease at 12 months, 96% pad-free continence preservation, and 84% retention of baseline sexual function. AngioDynamics referenced >2,600 global patients treated and said the TIME issue hits newsstands December 12.
AngioDynamics (NASDAQ: ANGO) reported strong fiscal Q1 2026 results, with net sales reaching $75.7 million, up 12.2% year-over-year. The Med Tech segment showed exceptional performance with 26.1% growth to $35.3 million, marking its fourth consecutive quarter of over 20% growth.
Key financial metrics include a gross margin of 55.3%, adjusted EBITDA of $2.2 million (compared to -$0.2M prior year), and adjusted loss per share of $0.10. The company ended Q1 with $38.8 million in cash and maintains a debt-free balance sheet.
Following strong performance, AngioDynamics raised its FY2026 guidance, now expecting net sales of $308-313 million and Med Tech growth of 14-16%. The company achieved significant clinical milestones with first patient enrollments in both AMBITION BTK and RECOVER-AV trials, while the NanoKnife PRESERVE study results were published in European Urology.
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has scheduled its fiscal 2026 first quarter financial results announcement for October 2, 2025, before market open.
The company will host a conference call at 8:00 AM ET on the same day, accessible via phone (1-877-407-0784 domestic, +1-201-689-8560 international) and webcast through their investor relations website. A replay will be available until October 9, 2025, using passcode 13755707.
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular systems and cancer treatment, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Jim Clemmer, President and CEO, and Stephen Trowbridge, EVP and CFO, will conduct a fireside chat presentation on August 12, 2025, at 9:00 a.m. ET.
Investors can access the live webcast through the company's investor relations website at www.angiodynamics.com, where a replay will also be available after the event.
AngioDynamics (NASDAQ: ANGO) has announced the enrollment of its first patient in the AMBITION BTK clinical trial, investigating the effectiveness of their Auryon Atherectomy System combined with balloon angioplasty for treating Critical Limb Ischemia (CLI).
The trial will be a multicenter, randomized controlled study involving up to 224 patients across 30 sites, with a parallel registry enrolling up to 1,500 additional patients. The study aims to evaluate freedom from major amputation, freedom from clinically driven target lesion revascularization, and primary patency at 12 months.
The Auryon laser system has already treated over 100,000 patients worldwide and can address all infrainguinal lesion types. This trial is particularly significant as CLI affects a large patient population, with untreated cases facing a 20-25% risk of limb loss within one year.
AngioDynamics (NASDAQ: ANGO) announced the publication of its PRESERVE study results in European Urology, evaluating the NanoKnife System for prostate tissue ablation. The study, involving 121 patients across 17 clinical sites, demonstrated significant success in treating intermediate-risk prostate cancer.
Key findings include 84% of patients remaining free from clinically significant disease at 12 months post-procedure. The study showed remarkable quality-of-life preservation, with 96% maintaining urinary continence and 84% preserving sexual function. The NanoKnife System, which received FDA clearance for prostate tissue ablation in late 2024, uses non-thermal irreversible electroporation (IRE) technology to provide a minimally invasive treatment option.